ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: psoriasis

Long-Term Biologic Use May Not Raise Melanoma Risk

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot…

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

  |  

Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…

Shidlovski / shutterstock.com

Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

Bryn Nelson, PhD  |  

Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…

FDA Accelerates Approvals of Generic Versions of HCQ

U.S. Food and Drug Administration  |  

On April 7, the FDA approved an Abbreviated New Drug Application (ANDA) for Hydroxychloroquine Sulfate Tablets USP, 200 mg, for the treatment of: 1) uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; 2) chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and 3) treatment of acute and chronic…

Should Biologic Therapy in Dermatology Be Interrupted During the Pandemic?

Reuters Staff  |  

NEW YORK (Reuters Health)—The ongoing novel coronavirus pandemic has raised concerns about whether biologic therapy could make psoriasis patients more susceptible to SARS-CoV-2, the virus behind COVID-19. Mark Lebwohl, MD, from Icahn School of Medicine at Mount Sinai Hospital in New York and colleagues address this issue in a letter in the Journal of the…

Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts

  |  

ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…

From Chronic Low Back Pain to Axial Spondyloarthritis

Mike Fillon  |  

ATLANTA—Research into possible genetic drivers of the axial spondyloarthritis (axSpA), including the role of the genetic marker HLA-B27, is advancing, John D. Reveille, MD, professor and vice chair of medicine at the University of Texas McGovern Medical School, Houston, told attendees at the 2019 ACR/ARP Annual Meeting. Dr. Reveille delivered the Philip Hench, MD, Memorial…